- Home
- RPRX vs FMS Comparison
RPRX vs FMS Comparison
Compare RPRX & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | FMS |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 13.9B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RPRX | FMS |
|---|---|---|
| Price | $41.24 | $22.85 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 2 |
| Target Price | ★ $45.75 | $30.00 |
| AVG Volume (30 Days) | ★ 3.4M | 428.4K |
| Earning Date | 02-10-2026 | 02-24-2026 |
| Dividend Yield | 2.17% | ★ 2.41% |
| EPS Growth | N/A | ★ 8.62 |
| EPS | 1.75 | ★ 2.86 |
| Revenue | $2,349,844,000.00 | ★ $23,046,819,198.00 |
| Revenue This Year | $37.66 | $2.13 |
| Revenue Next Year | $2.34 | $2.95 |
| P/E Ratio | $23.21 | ★ $15.59 |
| Revenue Growth | ★ 3.70 | 2.10 |
| 52 Week Low | $25.40 | $22.05 |
| 52 Week High | $41.24 | $30.46 |
Technical Indicators
Market Signals| Indicator | RPRX | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 70.38 | 34.68 |
| Support Level | $38.29 | $23.83 |
| Resistance Level | $39.46 | $23.84 |
| Average True Range (ATR) | 0.64 | 0.24 |
| MACD | 0.21 | -0.02 |
| Stochastic Oscillator | 97.91 | 0.00 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.